Antisense Therapeutics (ASX:ANP) has announced that it has received feedback on the Paediatric Investigation Plan for the development of ATL1102 for Duchenne muscular dystrophy from the Paediatric Committee of the European Medicines Agency.

Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the grant of patents by the respective agencies of the US and India for the manufacturing process for paxalisib.

Australian immunotherapy company Immutep (ASX:IMM) has announced a $60 million capital raise and approval for a phase one clinical trial of its lead investigative candidate as part of a triple combination for the treatment of various forms of solid tumour.

Responding to advances in science, revised Guidelines for Stem Cell Research and Clinical Translation have been published by the International Society for Stem Cell Research.

SUDA Pharmaceuticals (ASX:SUD) has announced it has signed a global, exclusive agreement with Imperial College London for a novel invariant Natural Killer T cell therapy platform.

Pfizer’s Centers for Therapeutic Innovation has entered a new oncology-focused research collaboration with the Melbourne-based St Vincent’s Institute of Medical Research.

Australian regenerative medicine company Orthocell (ASX:OCC) has announced the first interim data of all patients in the CelGro nerve regeneration trial at 12 months post-treatment.

Australian company Starpharma (ASX:SPL) has announced that the sale of its COVID-19 nasal spray in the UK has been temporarily halted following correspondence from this UK regulator related to promotional claims.

ENA Respiratory, a biotechnology company developing a nasal spray for the prevention of COVID-19 and other respiratory viral infections, has secured up to $32 million in a capital raise.

The AusBiotech-led Team Australia delegation featured in the top four largest pavilions present at BIO Digital 2021 this week, where it proudly flew the virtual Australian flag and showcased Australia’s capabilities to a global audience.

Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and New Zealand patents have been granted for its CelGro collagen medical device platform for soft tissue regeneration applications.

A consortium of universities, hospitals and industry, led by Monash University and BiVACOR, has received $1 million in federal government funding to develop and commercialise a world-first durable Total Artificial Heart.  

The federal government has announced it will provide $5.9 million for projects focused on cancer prevention among women in vulnerable communities across the world through the Global Alliance for Chronic Diseases.

Nyrada (ASX:NYR) has announced the selection of a new version of its brain injury candidate (NYR-BI01) to be taken forward into its collaboration studies with the Walter Reed Army Institute of Research. 

Starpharma (ASX:SPL) has announced that its Australian developed anti-COVID nasal spray Viraleze is now registered for use in India.

Emyria (ASX:EMD) has announced the filing of further intellectual property protection in support of its EMD-004 drug development program targeting the symptoms of irritable bowel syndrome.